Thermo Fisher to buy Sweden’s Olink in $3.1bn deal

Under the terms of the transaction, Olink shareholders will receive $26 per share, which is a premium of around 74% to the closing share price on Monday.

Thermo Fisher said Olink offers leading solutions for advanced proteomics discovery and development, enabling biopharmaceutical companies and leading academic researchers to gain an understanding of disease at the protein level "rapidly and efficiently".

Thermo Fisher chairman, president and chief executive Marc N. Casper said: "The acquisition of Olink underscores the profound impact that proteomics is having as our customers continue to advance life science research and precision medicine.

"Olink’s proven and transformative innovation is highly complementary to our leading mass spectrometry and life sciences platforms. Our company is uniquely positioned to bring this technology to customers enabling them to meaningfully accelerate discovery and scientific breakthroughs."